In comparison to anti‐PD1 monotherapy, the combination of PCIF1 knockout with anti‐PD1 treatment significantly reduced tumour burden (Figure 7B), as evidenced by decreased lesion area and a reduced number of tumour lesions (Figure 7C and E). The gene discussed is PCIF1; the disease is neoplasm.